glp-1 and liver cirrhosis Your Liver: What to Monitor While on Semaglutide or Tirzepatide Exploring the Potential of GLP-1

Studies in animal models have shown an anorexigenic action of GIP receptor agonism [36] and a recent phase 1 clinical trial with a long-acting GIP RA found that repeated dosing for 4 weeks induced modest WL (1.9 to 3.1 kg vs

At this time, patients should not panic, but they should be informed

In a head-to-head trial against semaglutide (the SURPASS-2 trial), tirzepatide produced significantly greater weight loss, with participants taking the highest dose of tirzepatide losing an average of 11.2 kg (24.7 lbs), compared to 5.7 kg (12.5 lbs) for those taking semaglutide 1 mg

While this is most common in people who use insulin, injection-technique guidance recommends rotating injection spots